HAS Healthcare Advanced Synthesis Acquires Cerbios-Pharma to Form Leading CDMO Group

Adragos Pharma Acquires Baccinex

February 6, 2025

Pharmaceuticals

Adragos Pharma, a Munich-headquartered CDMO, has acquired Baccinex, a Swiss sterile fill-finish specialist based in Courroux, Jura. The acquisition adds a US FDA- and EU-GMP-certified 6,200 m² facility and over 110 sterile fill-finish experts to Adragos' global manufacturing network, enhancing its clinical and commercial sterile manufacturing capabilities.

GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

October 29, 2024

Healthcare Services

GlycoMimetics entered into an acquisition agreement with privately held oncology-focused biotechnology company Crescent Biopharma. The combined company will operate under the name Crescent Biopharma, Inc., advancing Crescent’s precision-engineered biologics for solid tumors, including the lead program CR-001, alongside ADC programs CR-002 and CR-003, supported by approximately $200 million in committed financing. GlycoMimetics stockholders approved the proposed merger in June 2025, and the combined company is expected to begin trading on Nasdaq on June 16, 2025 under the new ticker.

Formosa Laboratories Acquires SynChem to Expand North American CDMO Footprint

June 3, 2024

Pharmaceuticals

Formosa Laboratories, Inc., a Taiwan-based API supplier and CDMO, has completed its acquisition of SynChem, Inc., a contract research laboratory in suburban Chicago. SynChem will operate as SynChem-Formosa with Dr. W. Paul Mar remaining as CEO as the combined operations expand Formosa's US CDMO capabilities for small-molecule APIs and ADC-related chemistries.

ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera

November 17, 2023

Healthcare Services

Global private equity healthcare specialist ARCHIMED acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and simultaneously merged them. The resulting Symbio Proinnovera is a dermatology-focused contract research organization (CRO) offering outsourced dermatological therapy formulation and clinical trial testing across the full development lifecycle.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

Biosynth Acquires Cambridge Research Biochemicals (CRB)

May 9, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical materials to the life science industry, has acquired Cambridge Research Biochemicals (CRB), a UK-based independent producer of custom peptides and antibody tools. The acquisition expands Biosynth's peptide and antibody capabilities in Europe, adding expertise in complex peptide chemistry, fluorescent dye labelling and custom antibody generation to its existing operations.